| Community Action Committee Of Pike County | |
|
621 Broadway St Portsmouth OH 45662-4788 | |
| (740) 961-4011 | |
| (740) 961-4010 |
| Full Name | Community Action Committee Of Pike County |
|---|---|
| Speciality | Clinic/Center |
| Location | 621 Broadway St, Portsmouth, Ohio |
| Authorized Official Name and Position | Gary Roberts (EXECUTIVE DIRECTOR) |
| Authorized Official Contact | 7402892371 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Community Action Committee Of Pike County 941 Market St Piketon OH 45661-9757 Ph: (740) 289-2371 | Community Action Committee Of Pike County 621 Broadway St Portsmouth OH 45662-4788 Ph: (740) 961-4011 |
| NPI Number | 1578974929 |
|---|---|
| Provider Enumeration Date | 05/19/2014 |
| Last Update Date | 05/19/2014 |
| Medicare PECOS PAC ID | 3173432762 |
|---|---|
| Medicare Enrollment ID | O20141022000689 |
News Archive
"Scientists and aid organizations gave the world plenty of time to prepare, but a late response by the world's donor nations cost 50,000 to 100,000 lives during last year's drought in the Horn of Africa region," the Christian Science Monitor's "Global News Blog" writes about a report released on Wednesday by Save the Children and Oxfam.
Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.
Touch Bionics, developer of advanced upper-limb bionic technologies, today announced the launch of the i-LIMB Pulse, an all-new version of the revolutionary i-LIMB Hand, the world's first commercially available bionic hand.
Cornell University researchers have discovered a likely origin of epithelial ovarian cancer (ovarian carcinoma), the fifth leading cause of cancer death among women in the United States.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578974929 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QP2300X | Clinic/center - Primary Care | (* (Not Available)) | Primary |
| Provider Name | Angela Migyanko |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1730301078 PECOS PAC ID: 8426013525 Enrollment ID: I20041201000062 |
News Archive
"Scientists and aid organizations gave the world plenty of time to prepare, but a late response by the world's donor nations cost 50,000 to 100,000 lives during last year's drought in the Horn of Africa region," the Christian Science Monitor's "Global News Blog" writes about a report released on Wednesday by Save the Children and Oxfam.
Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.
Touch Bionics, developer of advanced upper-limb bionic technologies, today announced the launch of the i-LIMB Pulse, an all-new version of the revolutionary i-LIMB Hand, the world's first commercially available bionic hand.
Cornell University researchers have discovered a likely origin of epithelial ovarian cancer (ovarian carcinoma), the fifth leading cause of cancer death among women in the United States.
› Verified 3 days ago
| Provider Name | Naomi K Blackburn |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1144467002 PECOS PAC ID: 2365599099 Enrollment ID: I20090415000018 |
News Archive
"Scientists and aid organizations gave the world plenty of time to prepare, but a late response by the world's donor nations cost 50,000 to 100,000 lives during last year's drought in the Horn of Africa region," the Christian Science Monitor's "Global News Blog" writes about a report released on Wednesday by Save the Children and Oxfam.
Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.
Touch Bionics, developer of advanced upper-limb bionic technologies, today announced the launch of the i-LIMB Pulse, an all-new version of the revolutionary i-LIMB Hand, the world's first commercially available bionic hand.
Cornell University researchers have discovered a likely origin of epithelial ovarian cancer (ovarian carcinoma), the fifth leading cause of cancer death among women in the United States.
› Verified 3 days ago
| Provider Name | Stephanie L Craft |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1144528019 PECOS PAC ID: 8820271711 Enrollment ID: I20110330001016 |
News Archive
"Scientists and aid organizations gave the world plenty of time to prepare, but a late response by the world's donor nations cost 50,000 to 100,000 lives during last year's drought in the Horn of Africa region," the Christian Science Monitor's "Global News Blog" writes about a report released on Wednesday by Save the Children and Oxfam.
Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.
Touch Bionics, developer of advanced upper-limb bionic technologies, today announced the launch of the i-LIMB Pulse, an all-new version of the revolutionary i-LIMB Hand, the world's first commercially available bionic hand.
Cornell University researchers have discovered a likely origin of epithelial ovarian cancer (ovarian carcinoma), the fifth leading cause of cancer death among women in the United States.
› Verified 3 days ago
| Provider Name | Crystal M Jordan |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1003255266 PECOS PAC ID: 5890939185 Enrollment ID: I20130926000895 |
News Archive
"Scientists and aid organizations gave the world plenty of time to prepare, but a late response by the world's donor nations cost 50,000 to 100,000 lives during last year's drought in the Horn of Africa region," the Christian Science Monitor's "Global News Blog" writes about a report released on Wednesday by Save the Children and Oxfam.
Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.
Touch Bionics, developer of advanced upper-limb bionic technologies, today announced the launch of the i-LIMB Pulse, an all-new version of the revolutionary i-LIMB Hand, the world's first commercially available bionic hand.
Cornell University researchers have discovered a likely origin of epithelial ovarian cancer (ovarian carcinoma), the fifth leading cause of cancer death among women in the United States.
› Verified 3 days ago
| Provider Name | Anthony H Arnett |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295177194 PECOS PAC ID: 1355576737 Enrollment ID: I20131022000386 |
News Archive
"Scientists and aid organizations gave the world plenty of time to prepare, but a late response by the world's donor nations cost 50,000 to 100,000 lives during last year's drought in the Horn of Africa region," the Christian Science Monitor's "Global News Blog" writes about a report released on Wednesday by Save the Children and Oxfam.
Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.
Touch Bionics, developer of advanced upper-limb bionic technologies, today announced the launch of the i-LIMB Pulse, an all-new version of the revolutionary i-LIMB Hand, the world's first commercially available bionic hand.
Cornell University researchers have discovered a likely origin of epithelial ovarian cancer (ovarian carcinoma), the fifth leading cause of cancer death among women in the United States.
› Verified 3 days ago
| Provider Name | Jade S Astorga |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1487089892 PECOS PAC ID: 0547499402 Enrollment ID: I20140219000550 |
News Archive
"Scientists and aid organizations gave the world plenty of time to prepare, but a late response by the world's donor nations cost 50,000 to 100,000 lives during last year's drought in the Horn of Africa region," the Christian Science Monitor's "Global News Blog" writes about a report released on Wednesday by Save the Children and Oxfam.
Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.
Touch Bionics, developer of advanced upper-limb bionic technologies, today announced the launch of the i-LIMB Pulse, an all-new version of the revolutionary i-LIMB Hand, the world's first commercially available bionic hand.
Cornell University researchers have discovered a likely origin of epithelial ovarian cancer (ovarian carcinoma), the fifth leading cause of cancer death among women in the United States.
› Verified 3 days ago
| Provider Name | Rebecca Brewster |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1144658527 PECOS PAC ID: 1153543210 Enrollment ID: I20141105002207 |
News Archive
"Scientists and aid organizations gave the world plenty of time to prepare, but a late response by the world's donor nations cost 50,000 to 100,000 lives during last year's drought in the Horn of Africa region," the Christian Science Monitor's "Global News Blog" writes about a report released on Wednesday by Save the Children and Oxfam.
Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.
Touch Bionics, developer of advanced upper-limb bionic technologies, today announced the launch of the i-LIMB Pulse, an all-new version of the revolutionary i-LIMB Hand, the world's first commercially available bionic hand.
Cornell University researchers have discovered a likely origin of epithelial ovarian cancer (ovarian carcinoma), the fifth leading cause of cancer death among women in the United States.
› Verified 3 days ago
| Provider Name | John K Loudermilk |
|---|---|
| Provider Type | Practitioner - Dentist |
| Provider Identifiers | NPI Number: 1215128715 PECOS PAC ID: 1355622713 Enrollment ID: I20161227001846 |
News Archive
"Scientists and aid organizations gave the world plenty of time to prepare, but a late response by the world's donor nations cost 50,000 to 100,000 lives during last year's drought in the Horn of Africa region," the Christian Science Monitor's "Global News Blog" writes about a report released on Wednesday by Save the Children and Oxfam.
Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.
Touch Bionics, developer of advanced upper-limb bionic technologies, today announced the launch of the i-LIMB Pulse, an all-new version of the revolutionary i-LIMB Hand, the world's first commercially available bionic hand.
Cornell University researchers have discovered a likely origin of epithelial ovarian cancer (ovarian carcinoma), the fifth leading cause of cancer death among women in the United States.
› Verified 3 days ago
| Provider Name | Joy Puckett |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1427509884 PECOS PAC ID: 8921412966 Enrollment ID: I20210202002418 |
News Archive
"Scientists and aid organizations gave the world plenty of time to prepare, but a late response by the world's donor nations cost 50,000 to 100,000 lives during last year's drought in the Horn of Africa region," the Christian Science Monitor's "Global News Blog" writes about a report released on Wednesday by Save the Children and Oxfam.
Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.
Touch Bionics, developer of advanced upper-limb bionic technologies, today announced the launch of the i-LIMB Pulse, an all-new version of the revolutionary i-LIMB Hand, the world's first commercially available bionic hand.
Cornell University researchers have discovered a likely origin of epithelial ovarian cancer (ovarian carcinoma), the fifth leading cause of cancer death among women in the United States.
› Verified 3 days ago
| Provider Name | Bryce Yates |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1487184446 PECOS PAC ID: 4688931298 Enrollment ID: I20210301001650 |
News Archive
"Scientists and aid organizations gave the world plenty of time to prepare, but a late response by the world's donor nations cost 50,000 to 100,000 lives during last year's drought in the Horn of Africa region," the Christian Science Monitor's "Global News Blog" writes about a report released on Wednesday by Save the Children and Oxfam.
Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.
Touch Bionics, developer of advanced upper-limb bionic technologies, today announced the launch of the i-LIMB Pulse, an all-new version of the revolutionary i-LIMB Hand, the world's first commercially available bionic hand.
Cornell University researchers have discovered a likely origin of epithelial ovarian cancer (ovarian carcinoma), the fifth leading cause of cancer death among women in the United States.
› Verified 3 days ago
| Provider Name | Bhupesh Kiran Mandali |
|---|---|
| Provider Type | Practitioner - Dentist |
| Provider Identifiers | NPI Number: 1255888392 PECOS PAC ID: 5294141511 Enrollment ID: I20210311002377 |
News Archive
"Scientists and aid organizations gave the world plenty of time to prepare, but a late response by the world's donor nations cost 50,000 to 100,000 lives during last year's drought in the Horn of Africa region," the Christian Science Monitor's "Global News Blog" writes about a report released on Wednesday by Save the Children and Oxfam.
Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.
Touch Bionics, developer of advanced upper-limb bionic technologies, today announced the launch of the i-LIMB Pulse, an all-new version of the revolutionary i-LIMB Hand, the world's first commercially available bionic hand.
Cornell University researchers have discovered a likely origin of epithelial ovarian cancer (ovarian carcinoma), the fifth leading cause of cancer death among women in the United States.
› Verified 3 days ago
| Provider Name | Rebecca E Hall |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1104471200 PECOS PAC ID: 2567869357 Enrollment ID: I20210921002532 |
News Archive
"Scientists and aid organizations gave the world plenty of time to prepare, but a late response by the world's donor nations cost 50,000 to 100,000 lives during last year's drought in the Horn of Africa region," the Christian Science Monitor's "Global News Blog" writes about a report released on Wednesday by Save the Children and Oxfam.
Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.
Touch Bionics, developer of advanced upper-limb bionic technologies, today announced the launch of the i-LIMB Pulse, an all-new version of the revolutionary i-LIMB Hand, the world's first commercially available bionic hand.
Cornell University researchers have discovered a likely origin of epithelial ovarian cancer (ovarian carcinoma), the fifth leading cause of cancer death among women in the United States.
› Verified 3 days ago
| Provider Name | Bailey Kathleen Caughlan |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1164186425 PECOS PAC ID: 8729479605 Enrollment ID: I20220104000831 |
News Archive
"Scientists and aid organizations gave the world plenty of time to prepare, but a late response by the world's donor nations cost 50,000 to 100,000 lives during last year's drought in the Horn of Africa region," the Christian Science Monitor's "Global News Blog" writes about a report released on Wednesday by Save the Children and Oxfam.
Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.
Touch Bionics, developer of advanced upper-limb bionic technologies, today announced the launch of the i-LIMB Pulse, an all-new version of the revolutionary i-LIMB Hand, the world's first commercially available bionic hand.
Cornell University researchers have discovered a likely origin of epithelial ovarian cancer (ovarian carcinoma), the fifth leading cause of cancer death among women in the United States.
› Verified 3 days ago
| Provider Name | Judith Ann Fulton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1821519943 PECOS PAC ID: 6608205760 Enrollment ID: I20220916000486 |
News Archive
"Scientists and aid organizations gave the world plenty of time to prepare, but a late response by the world's donor nations cost 50,000 to 100,000 lives during last year's drought in the Horn of Africa region," the Christian Science Monitor's "Global News Blog" writes about a report released on Wednesday by Save the Children and Oxfam.
Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.
Touch Bionics, developer of advanced upper-limb bionic technologies, today announced the launch of the i-LIMB Pulse, an all-new version of the revolutionary i-LIMB Hand, the world's first commercially available bionic hand.
Cornell University researchers have discovered a likely origin of epithelial ovarian cancer (ovarian carcinoma), the fifth leading cause of cancer death among women in the United States.
› Verified 3 days ago
| Provider Name | Catherine Hughes |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1780140475 PECOS PAC ID: 7517295371 Enrollment ID: I20231108001158 |
News Archive
"Scientists and aid organizations gave the world plenty of time to prepare, but a late response by the world's donor nations cost 50,000 to 100,000 lives during last year's drought in the Horn of Africa region," the Christian Science Monitor's "Global News Blog" writes about a report released on Wednesday by Save the Children and Oxfam.
Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.
Touch Bionics, developer of advanced upper-limb bionic technologies, today announced the launch of the i-LIMB Pulse, an all-new version of the revolutionary i-LIMB Hand, the world's first commercially available bionic hand.
Cornell University researchers have discovered a likely origin of epithelial ovarian cancer (ovarian carcinoma), the fifth leading cause of cancer death among women in the United States.
› Verified 3 days ago
News Archive
"Scientists and aid organizations gave the world plenty of time to prepare, but a late response by the world's donor nations cost 50,000 to 100,000 lives during last year's drought in the Horn of Africa region," the Christian Science Monitor's "Global News Blog" writes about a report released on Wednesday by Save the Children and Oxfam.
Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.
Touch Bionics, developer of advanced upper-limb bionic technologies, today announced the launch of the i-LIMB Pulse, an all-new version of the revolutionary i-LIMB Hand, the world's first commercially available bionic hand.
Cornell University researchers have discovered a likely origin of epithelial ovarian cancer (ovarian carcinoma), the fifth leading cause of cancer death among women in the United States.
› Verified 3 days ago
Shawnee Family Health Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 901 Washington St, Portsmouth, OH 45662 Phone: 740-355-8686 Fax: 740-353-1662 | |
Community Action Committee Of Pike County Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 717 5th St, Portsmouth, OH 45662 Phone: 740-354-6605 | |
Community Action Committee Of Pike County Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 717 5th St, Portsmouth Family Health Center, Portsmouth, OH 45662 Phone: 740-354-6605 | |
Cardiac Examination, Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1805 27th St, Portsmouth, OH 45662 Phone: 740-356-8681 Fax: 740-353-7900 | |
John Ditraglia Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 717 5th St, Portsmouth, OH 45662 Phone: 740-354-6605 Fax: 740-354-1565 | |
Kings Daughters Portsmouth Internal Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1729 Kinneys Ln Ste 201, Portsmouth, OH 45662 Phone: 740-355-8930 Fax: 740-354-7900 | |
Shawnee Family Health Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 901 Washington St, Portsmouth, OH 45662 Phone: 740-354-7702 Fax: 740-353-1662 |